News | February 27, 2026
Novo Nordisk & Vivtex team up to revolutionize oral hiologics
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The innovative eyedrop targets inflammation and pain following ocular surgery
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
Subscribe To Our Newsletter & Stay Updated
